Abstract

Pharmacotherapy of epilepsy requires deep knowledge of anti-epileptic drugs (AEDs), including the following issues: spectrum of therapeutic efficacy and therapeutic strength, adverse effects (especially severe and life-threatening adverse reactions); specific features of pharmacokinetics, pharmacodynamics, and drug interactions; titration rate, the need for laboratory tests during treatment, pharmacoeconomic components. The main properties of antiepileptic drugs are defined by their mechanisms of action. Today, particular attention is paid to the drugs with broad spectrum activity, which give an ability to use them in patients with so-called undifferentiated epilepsies. In this article, the authors describe their own experience in optimization of antiepileptic therapy in a group of 141 patients with various forms of epilepsy. This new optimized strategy implies inclusion of modern broad spectrum AEDs in treatment schemes along with the reduction in use of narrow spectrum drugs. Moreover, polytherapy was used in most of the cases after treatment regimen correction. All the measures allowed to achieve remission in about half of the patients with epilepsy earlier considered as incurable.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.